JP2025522295A5 - - Google Patents

Info

Publication number
JP2025522295A5
JP2025522295A5 JP2024569265A JP2024569265A JP2025522295A5 JP 2025522295 A5 JP2025522295 A5 JP 2025522295A5 JP 2024569265 A JP2024569265 A JP 2024569265A JP 2024569265 A JP2024569265 A JP 2024569265A JP 2025522295 A5 JP2025522295 A5 JP 2025522295A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
antibody
antigen
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024569265A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025522295A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/067312 external-priority patent/WO2023230445A2/en
Publication of JP2025522295A publication Critical patent/JP2025522295A/ja
Publication of JP2025522295A5 publication Critical patent/JP2025522295A5/ja
Pending legal-status Critical Current

Links

JP2024569265A 2022-05-23 2023-05-22 インフルエンザノイラミニダーゼに対する広域中和抗体 Pending JP2025522295A (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202263345016P 2022-05-23 2022-05-23
US63/345,016 2022-05-23
US202263427799P 2022-11-23 2022-11-23
US63/427,799 2022-11-23
US202263430319P 2022-12-05 2022-12-05
US63/430,319 2022-12-05
US202363481977P 2023-01-27 2023-01-27
US63/481,977 2023-01-27
US202363488433P 2023-03-03 2023-03-03
US63/488,433 2023-03-03
US202363493057P 2023-03-30 2023-03-30
US63/493,057 2023-03-30
PCT/US2023/067312 WO2023230445A2 (en) 2022-05-23 2023-05-22 Broadly neutralizing antibodies against influenza neuraminidase

Publications (2)

Publication Number Publication Date
JP2025522295A JP2025522295A (ja) 2025-07-15
JP2025522295A5 true JP2025522295A5 (https=) 2026-05-01

Family

ID=86904151

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024569265A Pending JP2025522295A (ja) 2022-05-23 2023-05-22 インフルエンザノイラミニダーゼに対する広域中和抗体

Country Status (8)

Country Link
EP (1) EP4529464A2 (https=)
JP (1) JP2025522295A (https=)
KR (1) KR20250030975A (https=)
CN (1) CN119907679A (https=)
AU (1) AU2023277611A1 (https=)
CA (1) CA3256285A1 (https=)
TW (1) TW202411247A (https=)
WO (1) WO2023230445A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026021428A1 (en) * 2024-07-23 2026-01-29 Westlake University Anti-neuraminidase antibodies and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
ATE492562T1 (de) 2003-09-24 2011-01-15 Kyowa Hakko Kirin Co Ltd Rekombinanter antikörper gegen humanen insulin- like growth factor
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8119772B2 (en) 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
US10519251B2 (en) 2013-12-30 2019-12-31 Epimab Biotherapeutics, Inc. Fabs-in-tandem immunoglobulin and uses thereof
WO2016124682A1 (en) * 2015-02-05 2016-08-11 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza neuraminidase
EP3294774B1 (en) 2015-05-13 2024-08-28 Zumutor Biologics, Inc. Afucosylated protein, cell expressing said protein and associated methods
WO2019024979A1 (en) 2017-07-31 2019-02-07 Institute For Research In Biomedicine FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
AU2018334886B2 (en) 2017-09-22 2025-06-26 WuXi Biologics Ireland Limited Novel bispecific polypeptide complexes
PH12022553569A1 (en) 2020-06-24 2023-04-12 Humabs Biomed Sa Engineered hepatitis b virus neutralizing antibodies and uses thereof
AU2021381778A1 (en) * 2020-11-23 2023-06-22 Humabs Biomed Sa Broadly neutralizing antibodies against influenza neuraminidase

Similar Documents

Publication Publication Date Title
US11787860B2 (en) Anti-CD47 antibodies and uses thereof
US10544212B2 (en) Anti-IL-33 antibodies, compositions, methods and uses thereof
JP6943549B2 (ja) Cd47に対するヒト化及びキメラモノクローナル抗体
US20230112916A1 (en) Neutralizing anti-influenza binding molecules and uses thereof
AU2016214304A1 (en) Binding molecules directed against influenza hemagglutinin and uses thereof
US12076413B2 (en) Compositions and methods for modulating delta gamma chain mediated immunity
US12331104B2 (en) Hepatitis B antibodies
JP6162319B2 (ja) ヒト化抗n2抗体
US20240092875A1 (en) Sars-cov-2 antibodies for treatment and prevention of covid-19
JP2023551668A5 (https=)
CN115551885A (zh) 用于治疗和预防流感的组合物和方法
TW202342095A (zh) 用於治療和預防covid—19之組成物
CA3199429A1 (en) Anti-influenza antibodies and combinations thereof
CA3199023A1 (en) Broadly neutralizing antibodies against influenza neuraminidase
JP2025522295A5 (https=)
JP2023551666A5 (https=)
CA3197537A1 (en) Antibodies against influenza a viruses
US20250154287A1 (en) ANTI-MIGIS-alpha ANTIBODIES AND METHODS OF USE THEREOF
US20250376511A1 (en) BINDING PROTEINS THAT TARGET aC1s, TfR, OR BOTH, AND COMPOSITIONS THEREOF
US12071481B2 (en) Anti-CD47 antibodies and uses thereof
US20260035439A1 (en) Anti-Sars-COV-2 Antibodies and Uses Thereof
JP2025094941A (ja) Lag-3アゴニスト抗体